Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution

Lamb, Edmund J, Levey, Andrew S, Stevens, Paul E · 2013 · Clinical Chemistry

Abstract

In 2002, the US National Kidney Foundation published their seminal Kidney Disease Outcome Quality Initiative (KDOQI)4 guideline on chronic kidney disease (CKD) (1). This guideline led to a revolution in the detection and management of CKD. Two of the cornerstones of kidney disease diagnosis and management—proteinuria and decreased glomerular filtration rate (GFR)—had always relied heavily on laboratory support. Inevitably, the guideline was avidly read by laboratory scientists and clinicians, with dramatic changes in practice ensuing. Implementation of the guideline was facilitated by the fact that a simple equation, the Modification of Diet in Renal Disease (MDRD) Study equation, had been published several years previously. This equation enabled estimation of GFR from the serum creatinine concentration, in addition to basic demographic details routinely supplied to laboratories. For the first time, a kidney disease definition and staging system were in use and linked directly to detection and management, and there was a simple and practical laboratory test available for the objective categorization of patients. Publication of the guideline contributed to an explosion in research, clinical evidence, and debate, in addition to the publication of other guidelines in other countries. There were also problems. The influence of creatinine method bias on the estimated GFR (eGFR) was perhaps the paramount problem, together with concerns of overdetection among some clinicians as the scale of the CKD “epidemic” came to be appreciated. Through joint efforts of the laboratory and nephrology community, the problems of standardization have largely been resolved. Some observers still have concerns about so-called disease labeling, but there is general agreement that a low GFR is associated with increased risk, regardless of age, sex, ethnicity, or underlying disease. The evidence generated in the last decade has driven an increased recognition of the need to revise the guideline and for increased sophistication. The work of KDOQI has been superseded by KDIGO (Kidney Disease Improving Global Outcomes). KDIGO's mission statement is “to improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines” (http://www.kdigo.org/about_us.php). The work group for the CKD guideline included an international group of kidney specialists, primary-care doctors, diabetologists, epidemiologists, a clinical chemist, administrators, and a professional evidence-review team that provided support. The group met between October 2010 and July 2011 to consider the evidence, and the guidance has now been published (2). What are the main implications of the new guideline for laboratories? Consistent with previous guidance, the new KDIGO guideline retains the diagnostic criteria for CKD: a GFR threshold <60 mL · min−1 · (1.73 m2)−1 or the presence of kidney damage (proteinuria, albuminuria, urinary sediment abnormalities, pathologic/imaging abnormalities, genetic disorders, or a history of renal transplantation). CKD is defined as an abnormality of kidney structure or function that has been present for ≥3 months and that has implications for health. Although the previous staging system was unidimensional (i.e., based on the GFR), the new guideline promotes a classification based on cause (C category), GFR (G category), and albuminuria (A category). The GFR categories remain broadly as previously, but GFR category 3 (moderately decreased) has now been divided into categories G3a [45–59 mL · min−1 · (1.73 m2)−1] and G3b [30–44 mL · min−1 · (1.73 m2)−1], which represent mildly to moderately decreased function and moderately to severely decreased function, respectively. The associations of lower categories of GFR with risks of metabolic and endocrine complications formed the basis of the original stratification into 5 stages. The current classification further acknowledges the importance of dividing the G3 category, because the data support the different outcomes and risk profiles in categories G3a and G3b. What has also become increasingly clear in the vast body of evidence since 2002—most notably the data provided by the CKD Prognosis Consortium (3)—is the graded relationship between increasing proteinuria and a variety of important outcomes, including all-cause mortality, cardiovascular disease, and kidney failure (Fig. 1). Consequently, an additional dimension has been added to the CKD staging system. Assignment to an albuminuria category is based on daily urinary albumin loss, generally measured as an albumin-to-creatinine ratio (ACR): A1 [<30 mg/day; ACR, <30 mg/g (<3 mg/mmol)], A2 [30–300 mg/day; ACR, 30–300 mg/g (3–30 mg/mmol)], and A3 [>300 mg/day; ACR, >300 mg/g (>30 mg/mmol)]. Risk increases incrementally in both directions—down the GFR categories and from left to right across the albuminuria categories. This r

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2012.184259

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 169

Metadata

Authors
Lamb, E. J., Levey, A. S., & Stevens, P. E.
Venue
Clinical Chemistry
Published
2013-03-01
Volume
59
Issue
3
Pages
462-465
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2133274082
Cited by
169
References
3
FWCI
4.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution. https://app.cochat.ai/papers/10.1373/clinchem.2012.184259
The paper
Lamb, E. J., Levey, A. S., & Stevens, P. E. (2013). The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution. Clinical Chemistry. https://doi.org/10.1373/clinchem.2012.184259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.